Amgen, Inc.

Amgen, Inc.

Sector: Biological Products Except Diagnostic Substances Region: CA, United States

: | Nasdaq: AMGN | Hong Kong Stock Exchange: 4332 | Frankfurt Stock Exchange: AMG

Similar to: NPS Pharmaceuticals, Inc., BioTime, Inc., Bebra Biogas Holding AG

Amgen, Inc. is a biotechnology medicines company, which discovers, develops, manufactures and markets medicines for grievous illnesses. The company focuses on human therapeutics and concentrates on innovating novel medicines based on advances in cellular and molecular biology. It markets recombinant protein therapeutics in supportive cancer care, nephrology and inflammation. The cpmpany's products include Neulasta, a pegylated protein, based on the Filgrastim molecule and NEUPOGEN, a recombinant-methionyl human granulocyte colony-stimulating factor both of which selectively stimulate the production of neutrophils; Enbrel, an inhibitor of tumor necrosis factor, a substance that plays a role in the body's response to inflammatory diseases; Sensipar/Mimpara, a small molecule calcimimetic that lowers serum calcium levels; Vectibix, a monoclonal antibody that binds specifically to the epidermal growth factor receptor; and Nplate, a thrombopoietin receptor agonist that mimics endogenous TPO, the primary driver of platelet production. Amgen was founded by William K. Bowes, Jr., Franklin Pitcher Johnson, Jr., George B. Rathmann and Joseph Rubinfeld on April 8, 1980 and is headquartered in Thousand Oaks, CA.

Latest Media

Warning! Third-party cookies must be enabled to view SlideShare presentations. ×

Having trouble?

Amgen Reaffirms 2011 Through 2015 Guidance

Amgen, Inc. video

Amgen Reaffirms 2011 Through 2015 Guidance

Amgen, Inc. video

The Amgen Difference

Amgen, Inc. video

Manufacturing Process Changes for Biologics: Experience Matters


Robert A. Bradway, President and Chief Executive Officer
Robert A. Bradway became Amgen’s president and chief executive officer in May 2012. Bradway served as the company’s president and chief operating officer from May 2010 to May 2012 and was appointed to the Amgen Board of Directors in October 2011. He joined the company in 2006 as vice president, Operations Strategy, and served as executive vice president and chief financial officer from April 2007 to May 2010. Prior to joining Amgen, he was a managing director at Morgan Stanley in London where he had responsibility for the firm’s banking department and corporate finance activities in Europe. Bradway joined Morgan Stanley in New York as a health care industry investment banker in 1985 and moved to London in 1990 where he served as head of the firm’s international health care investment banking activities until assuming broader corporate finance management responsibilities. Bradway holds a bachelor’s degree in Biology from Amherst College and an MBA from Harvard University. He is a member of the board of directors of Norfolk Southern Corporation.
Jonathan M. Peacock, EVP and CFO
Jonathan M. Peacock joined Amgen as chief financial officer in September 2010. In this role, he is responsible for finance, investor relations operations and strategy and corporate development.
Peacock joined Amgen from Novartis Pharmaceutical AG, where he had served as chief financial and administration officer since 2005. He also was responsible for IT, Purchasing, Strategic Planning and Mergers and Acquisitions at Novartis. In addition, Peacock was responsible for Novartis’ malaria program, a corporate citizenship initiative in conjunction with the major donor organizations, to supply the company’s malaria medicine at cost to countries throughout Africa.
Previously, Peacock was a partner at McKinsey and Company, working for the consulting firm’s Amsterdam, Zurich and London offices. He also was a partner at Price Waterhouse in New York and London. He has an MA degree in Economics from the University of St. Andrews in Scotland and is a Chartered Accountant.
Madhavan Balachandran, EVP, Operations
Madhavan (Madhu) Balachandran is Amgen’s executive vice president, Operations. Balachandran oversees the company's global manufacturing operations, quality, product and process engineering, and capital projects. From October 2007 to August 2012, Balachandran served as Amgen’s senior vice president, Manufacturing, responsible for operations at Amgen’s commercial manufacturing locations and Amgen’s supply chain. Before that he spent five years in Puerto Rico as vice president, Puerto Rico Operations, with responsibility for all manufacturing in Puerto Rico as well as major capital projects designed to establish a bulk manufacturing operation on the island. Since joining Amgen in 1997, Balachandran also held roles as vice president, Information Management, and director, Engineering Operations Services. Before joining Amgen, Balachandran worked in a number of professional and senior management roles at Burroughs Wellcome, Battelle Memorial Institute, and Copley Pharmaceuticals in engineering, manufacturing, and consulting. Balachandran holds a bachelor’s degree in chemical engineering from the Indian Institute of Technology, Bombay, an MS in chemical engineering from the State University of New York in Buffalo, and an MBA from East Carolina University.

News & Analysis

You may also be interested in: